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Abstract
Prebiotics alter bacterial content in the colon, and therefore could be useful for obesity management. We investigated the changes following
addition of inulin oligofructose (IO) in the food of rats fed either a corn starch (C) diet or a high-carbohydrate, high-fat (H) diet as a model of
diet-induced metabolic syndrome. IO did not affect food intake, but reduced body weight gain by 5·3 and 12·3% in corn starch + inulin
oligofructose (CIO) and high-carbohydrate, high-fat with inulin oligofructose (HIO) rats, respectively. IO reduced plasma concentrations of
free fatty acids by 26·2% and TAG by 75·8% in HIO rats. IO increased faecal output by 93·2%, faecal lipid excretion by 37·9% and weight of
caecum by 23·4% and colon by 41·5% in HIO rats. IO improved ileal morphology by reducing inﬂammation and improving the density of
crypt cells in HIO rats. IO attenuated H diet-induced increases in abdominal fat pads (C 275 (SEM 19), CIO 264 (SEM 40), H 688 (SEM 55), HIO 419
(SEM 32)mg/mm tibial length), fasting blood glucose concentrations (C 4·5 (SEM 0·1), CIO 4·2 (SEM 0·1), H 5·2 (SEM 0·1), HIO 4·3 (SEM 0·1)mmol/l),
systolic blood pressure (C 124 (SEM 2), CIO 118 (SEM 2), H 152 (SEM 2), HIO 123 (SEM 3)mmHg), left ventricular diastolic stiffness
(C 22·9 (SEM 0·6), CIO 22·9 (SEM 0·5), H 27·8 (SEM 0·5), HIO 22·6 (SEM 1·2)) and plasma alanine transaminase (C 29·6 (SEM 2·8), CIO 32·1 (SEM 3·0),
H 43·9 (SEM 2·6), HIO 33·6 (SEM 2·0)U/l). IO attenuated H-induced increases in inﬂammatory cell inﬁltration in the heart and liver, lipid droplets
in the liver and plasma lipids as well as impaired glucose and insulin tolerance. These results suggest that increasing soluble ﬁbre intake with
IO improves signs of the metabolic syndrome by decreasing gastrointestinal carbohydrate and lipid uptake.
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Functional foods are differentiated from other foods by their
ability to improve health and well-being or reduce the risk of
disease, in addition to providing adequate nutrition(1,2). These
foods increase the ﬁbre content of the diet and include cereals,
fruits, vegetables, dried beans and lentils. These ﬁbre-
containing foods contain fructan-type oligosaccharides such as
inulin, an important dietary component since pre-historic
times(3). Food ﬁbre may act as a prebiotic by being resistant
to gastric acidity and enzymes such as α-glucosidase, maltase,
isomaltase and sucrase, and then undergoing fermentation by
bacteria in the colon to SCFA that promote the growth of
Biﬁdobacterium and Lactobacillus species(4). These changes in
the gut bacteria are associated with prevention or postpone-
ment of CVD with hypercholesterolaemia, osteoporosis,
diabetes, gastrointestinal infections and gut inﬂammation(4).
The WHO-recommended consumption of dietary ﬁbre of 25 g/d
is rarely achieved in many countries, such as those with
Western-style diets including the USA with an estimated
average ﬁbre intake of 15 g/d(5). Dietary consumption of inulin
has been reported as 1–4 g/d in the USA and 3–11 g/d in
Europe, below the tolerated dose of 10–20 g/d(6). Commer-
cially, inulin is mostly extracted from chicory root, although it
is present in many foods such as wheat, onions, bananas,
Jerusalem artichoke and leeks; inulin has widespread uses in
the pharmaceutical industry(7). Inulin is a mixture of linear
fructose polymers or fructans of two to sixty units each linked
by unique β(2–1) bonds with a glucose unit linked by an α(1–2)
bond at the end of each chain(8,9). These β(2–1) bonds cannot be
hydrolysed by salivary or pancreatic enzymes as with typical
carbohydrates, and therefore inulin has a reduced energy value
as well as dietary prebiotic effects(8,9). Oligofructose, a term
describing fructo-oligosaccharides, refers to a hydrolysed form of
inulin with two–ten monosaccharide units, possibly with a glucose
terminal unit(8). Functional foods have been studied as possible
lifestyle changes to control obesity and reduce associated health
risks(9). Obesity and dyslipidaemia are important facets of the
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metabolic syndrome. Intervention with inulin oligofructose (IO)
decreased energy intake and fat mass in rats fed a high-fat diet(10),
promoted satiety(11,12) and improved lipid metabolism, although
results in humans have been less consistent(13).
Rats fed a high-carbohydrate, high-fat diet mimic the
cardiovascular, liver and metabolic changes of the metabolic
syndrome in humans(14). In this study, we have determined
whether addition of IO as a dietary intervention reversed the
responses to this obesogenic diet in rats. Gastrointestinal, meta-
bolic, liver and cardiovascular parameters were measured for this
comparison. Orafti (R) Synergy1 is an oligofructose-enriched
inulin mixture comprised of 92 (SEM 2)% IO as a blended mixture
of equal parts of inulin and oligofructose(15,16). Our hypothesis
was that addition of IO will reverse obesity-related changes to the
gastrointestinal tract leading to reversal of changes in abdominal
fat pads, systolic blood pressure (SBP), heart and liver structure
and function, and reduced inﬁltration of inﬂammatory cells in
our rat model of the metabolic syndrome.
Methods
Rats and diets
Male Wistar rats (n 48, 8–9 weeks old; initial body weight 336
(SEM 2) g) supplied by the Animal Resource Centre in Perth,
Australia, were individually housed in a temperature-controlled
(20± 2°C), 12-h light–12h dark cycle environment with free
access to water and rat diet at the University of Southern
Queensland Animal House. All the experiments were approved
by the Animal Ethics Committees of The University of Queens-
land and the University of Southern Queensland under the
guidelines of the National Health and Medical Research Council
of Australia. Rats were randomly divided into four groups (twelve
each) and fed corn starch (C), corn starch + 5% inulin
oligofructose (CIO), a high-carbohydrate, high-fat diet (H) and
a high-carbohydrate, high-fat + inulin oligofructose diet (HIO).
Body weight and food and water intakes were measured
daily, and feed efﬁciency (%) was calculated(14,17). The
preparation and macronutrient composition of basal diets,
including the dietary fatty acid proﬁles, have been detailed
previously(14,18). The IO-containing diets were prepared by
adding 5% of IO replacing an equivalent amount of water in the
diet. The IO diets were administered for 8 weeks, starting
8 weeks after initiation of the corn starch or high-carbohydrate,
high-fat diet. Drinking water for H and HIO rats was augmented
with 25% fructose for the duration of the study.
Cardiovascular measurements
SBP was measured under light sedation with Zoletil (tiletamine
15mg/kg, zolazepam 15mg/kg by intraperitoneal injection;
Virbac), using a MLT1010 Piezo-Electric Pulse Transducer and
an inﬂatable tail-cuff connected to a MLT844 Physiological
Pressure Transducer using PowerLab data acquisition unit
(AD Instruments Australia and Paciﬁc Islands)(14,17).
Echocardiographic examination (Philips/Hewlett Packard
Sonos 5500, 12MHz transducer; Philips Healthcare) was per-
formed at 16 weeks(14,17). The ventricular contractility indices
were calculated, including ratio of SBP:left ventricular internal
diameter in systole (LVIDs), ratio of SBP:systolic volume and ratio
of end-systolic stress (ESS):LVIDs(14,19). Left ventricular (LV)
function of rats was assessed using the Langendorff heart pre-
paration(14,17). Terminal anaesthesia was induced via intraper-
itoneal injection of pentobarbitone sodium (Lethabarb®, 100mg/
kg). Heparin (200 IU; Sigma-Aldrich Australia) was administered
through the right femoral vein before blood (approximately 5ml)
was taken from the abdominal aorta. Isovolumetric ventricular
function was measured by inserting a latex balloon catheter into
the left ventricle of the isolated heart connected to a Capto SP844
MLT844 physiological pressure transducer and Chart software
on a MacLab system (AD Instruments Australia and Paciﬁc
Islands)(14–16).
Aortic contraction was determined using thoracic aortic rings
(approximately 4mm in length) suspended in an organ bath
chamber with a resting tension of approximately 10mN.
Cumulative concentration–response (contraction) curves
were measured for noradrenaline (Sigma-Aldrich Australia);
concentration–response (relaxation) curves were measured for
acetylcholine (Sigma-Aldrich Australia) or sodium nitroprusside
(Sigma-Aldrich Australia) in the presence of a submaximal
(70%) contraction to noradrenaline(14,17).
Oral glucose and insulin tolerance tests
For oral glucose tolerance test, basal blood glucose concentra-
tions were measured in blood collected from the tail veins of
overnight food-deprived rats using Medisense Precision Q.I.D
glucose meter (Abbott Laboratories). Fructose-supplemented
drinking water in the H and HIO groups was replaced with
normal water for the overnight food-deprivation period(14,20).
Rats were administered 2 g/kg body weight of glucose as a 40%
aqueous solution via oral gavage. Tail vein blood samples were
collected at 30, 60, 90 and 120min following glucose adminis-
tration. Insulin tolerance testing was performed after 5 h of food
deprivation in rats administered an intraperitoneal injection of
0·33 IU insulin/kg body weight. Tail vein blood samples were
collected at 15, 30, 45, 60, 90 and 120min for blood glucose
measurements after intraperitoneal insulin administration(14,20).
Body composition measurements
Dual energy X-ray absorptiometric (DXA) measurements were
performed on rats after 16 weeks of feeding, 2 d before rats
were euthanised for pathophysiological assessments, using a
Norland XR36 DXA instrument (Norland Corp.). DXA scans
were analysed using the manufacturer’s recommended software
for use in laboratory animals (Small Subject Analysis Software,
version 2.5.3/1.3.1; Norland Corp.)(14). The precision error of
lean mass for replicate measurements, with repositioning, was
3·2%. The visceral adiposity index (%) was calculated(14,17).
Organ measurements
The right and left ventricles were separated following
perfusion experiments and weighed. Liver and retroperitoneal,
epididymal and omental fat pads were dissected following heart
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removal and blotted dry for weighing. Organ weights were
normalised relative to the tibial length at the time of their
removal (in mg/mm)(14,17). The stomach, small intestine,
caecum and colon weight with contents were weighed and
measured. Weights were normalised relative to the tibial
length at the time of their removal (in mg/mm). The lengths of
the small intestine and colon (proximal and distal colon) were
measured using a standard ruler(21,22).
Lipid excretion and faecal output analysis
After 16 weeks, C, CIO, H and HIO rats (six each) were indi-
vidually housed in metabolic cages for 12 h, with the same food
and water. Faeces from individual rats were collected, weighed
and stored in an airtight, sealed container at −20°C for later
measurements. The faecal samples were powdered using a
mortar and pestle. Dietary lipids were extracted from 1 g of
powdered faecal material by manual solvent extraction using a
2:1 chloroform–methanol mixture with 0·1% vitamin E as an
antioxidant. The solvent faecal matter was mixed on a rotating
device for 40min with 20-ml chloroform–methanol solvent and
then centrifuged at 2500 rpm for 5min. The extraction proce-
dure was repeated twice with subsequent washing with double-
distilled water to remove all polar material. Extracts were
pooled, and the chloroform–methanol solution was evaporated
under a stream of N2 on a hot plate at 60°C until the beakers
reached constant weight, allowing calculation of gravimetric
extractable lipid content(23). The percentage lipid excretion was
calculated using the following formula: ((amount of lipid
excreted (g)/total amount of lipid consumed (g))× 100)). The
amount of extractable lipids present in either C or H diets
(6·2 and 187 g/kg diet, respectively) was determined(24).
Histology
Only two rats per group were allocated for histological analysis;
two slides were prepared for each tissue specimen, and two
random, non-overlapping ﬁelds per slide were obtained. Imme-
diately after removal, heart and liver tissues were ﬁxed in 10%
neutral buffered formalin for 3 d and then dehydrated and
embedded in parafﬁn wax(14,24). Thin sections (5μm) of the left
ventricle and the liver were cut and stained with haematoxylin–
eosin stain for determining inﬂammatory cell inﬁltration with 20×
and fat vacuole enlargement with 20× objectives using an
Olympus BX51 microscope (Olympus). Collagen distribution was
evaluated in the left ventricle with picrosirius red stain. Laser
confocal microscopy (Zeiss LSM 510 upright Confocal Micro-
scope; Carl Zeiss) with colour intensity quantiﬁed using
NIH-imageJ software (National Institute of Health) was used to
determine the extent of collagen deposition in the selected tissue
sections(14,24). Faecal matter-free ileal tissue segments were
removed from the mesenteric border by rinsing and ﬁxed in 10%
neutral buffered formalin for 3 d, dehydrated and embedded in
parafﬁn wax(14,24). The ileal segments were cut at 5-μm thickness
and stained with haematoxylin–eosin for determining inﬂamma-
tory cell inﬁltration, mucosal thickening, gland (crypts) cell
proliferation and morphology with 20× objective using an
Olympus BX51 microscope (Olympus)(25,26).
Plasma analyses
Blood samples were centrifuged at 5000 g for 15min within
30min of collection into heparinised tubes. Plasma samples
were separated and transferred to Eppendorf tubes for storage
at −20°C before analysis. Activities of plasma liver enzymes,
alanine transaminase (ALT) and aspartate transaminase (AST),
and concentrations of plasma analytes including NEFA, TAG
and total cholesterol were determined using kits and
controls supplied by Olympus using an Olympus analyser
(AU 400)(14,24).
Inulin oligofructose mixture
Orafti Synergy1, an oligofructose-enriched inulin mixture(15),
supplied by Invita Australia Pty Ltd, contained 92 (SEM 2) g of
oligofructose+ inulin, 8 (SEM 2) g of sugars (glucose+ fructose+
sucrose) and sulphated ash content <0·2g/100 g. The energy
value of Synergy1 mixture was 693kJ/100 g of powdered mixture.
Statistical analysis
All data are presented as means with their standard errors.
Results were tested for variance using Bartlett’s test, and vari-
ables that were not normally distributed were transformed
(using log 10 function) before statistical analyses. Data from C,
CIO, H and HIO rats were tested by two-way ANOVA. When
interaction and/or the main effects were signiﬁcant, means
were compared using Newman–Keuls multiple comparison
post hoc test. Where transformations did not result in normality
or constant variance, a Kruskal–Wallis non-parametric test was
performed. A P value of <0·05 was considered as statistically
signiﬁcant. All statistical analyses were performed using
GraphPad Prism version 5.00 for Windows.
Results
Inulin oligofructose treatment on food intake, body weight,
plasma lipid proﬁle and fat mass
Feeding a high-energy diet together with fructose-
supplemented drinking water reduced food and water intake
in H and HIO rats compared with C and CIO rats (Table 1). IO
in CIO and HIO rats did not change food or water intake,
compared with the respective C and H rats (Table 1). With
increased energy in the diet, H rats increased energy intake with
a corresponding increase in feed conversion efﬁciency and
body weight gain compared with C and CIO rats (Table 1). IO
did not change energy intake in HIO rats, but increased energy
intake in CIO rats compared with C rats (Table 1). IO attenuated
body weight gain with reduced feed conversion efﬁciency in
CIO or HIO rats (Table 1).
The high-energy diet with increased simple carbohydrates and
SFA increased the plasma concentrations of TAG, NEFA and total
cholesterol in H rats compared with C rats (Table 1). IO
improved the lipid proﬁle with reduced plasma concentration of
TAG and NEFA in HIO rats, whereas in CIO rats plasma NEFA
concentrations increased compared with C rats (Table 1).
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However, plasma cholesterol concentrations remained unchan-
ged in CIO and HIO rats compared with C and H rats (Table 1).
H rats had increased total body fat, abdominal fat mass and
abdominal circumference compared with C rats (Table 2). IO
reduced abdominal (39%) and total body fat mass (42%)
associated with reduced abdominal circumference (11%) in
HIO rats (Table 2). IO reduced total body fat mass (27%) in
CIO compared with C rats without changing abdominal
circumference (Table 2).
Inulin oligofructose treatment on gut morphology and
function and faecal output
H rats had increased weight of stomach, small intestine, caecum
and colon with contents as well as total weight compared with
C rats (Table 3). H rats showed elongated ileal crypt cells with a
reduced density and an increased intestinal ileal inﬂammation
compared with C rats (Fig. 1(a) and (c)). IO increased caecum
and colon weights in CIO and HIO rats (Table 3). Stool
production increased by 1·9 or 1·7 g/12 h in CIO and HIO rats
compared with C and H rats (Table 3). IO improved gut mor-
phology with reduced intestinal ileal inﬂammation, enhanced
density of crypt cells with no signs of elongation and
improved villi morphology in HIO rats compared with H rats
(Fig. 1(c) and (d)). Furthermore, no changes were observed in
the length of gastrointestinal segments (Table 3).
Inulin oligofructose treatment on liver structure and
function and glucose and insulin responses
H-rats showed increased liver weights (Table 4) with enhanced
fat accumulation and inﬁltration of inﬂammatory cells (Fig. 2(a),
(c), (e) and (g)) as well as increased plasma activities of the liver
enzymes, ALT and AST, compared with C rats (Table 4). IO
decreased liver weight by 16·7% and reversed all other liver
changes in HIO rats (Table 4; Fig. 2(c), (d), (g) and (h)).
Hyperglycaemia, impaired oral glucose tolerance and insulin
resistance were measured in H rats compared with C and CIO
rats (Table 4). IO improved the blood glucose proﬁle with
reduced fasting blood glucose concentrations associated with
improved oral glucose tolerance and insulin tolerance in HIO
rats compared with H rats (Table 4).
Inulin oligofructose treatment on cardiovascular structure
and function
H rats showed increased SBP (Table 5) as well as decreased
endothelium-dependent relaxation to acetylcholine (Fig. 3(C))
Table 1. Dietary intakes, plasma lipid profile and lipid output
(Mean values with their standard errors; eight to ten rats per group)
C CIO H HIO P
Variables Mean SEM Mean SEM Mean SEM Mean SEM Diet Treatment Interaction
Food intake (g/d) 31·8a 1·7 33·0a 2·2 20·9b 1·4 20·8b 1·2 <0·0001 0·73 0·68
Water intake (ml/d) 31·2a 1·7 32·7a 2·1 18·7b 1·5 19·3b 1·5 <0·0001 0·54 0·78
Energy intake (kJ/d) 362·4c 3·6 389·3b 5·5 438.6a 5·7 446·6a 5·5 <0·0001 0·0017 0·07
Feed conversion efficiency (%) 2·4b 0·1 0·9c 0·5 4·6a 0·3 1·8b 0·1 <0·0001 <0·0001 0·09
Body weight gain (%)* 8·7b 0·3 3·4c 2·1 20·2a 1·3 7·9b 0·6 <0·0001 <0·0001 0·0155
Plasma NEFA (mmol/l) 1·65c 0·27 2·93b 0·47 5·12a 0·33 3·78b 0·51 <0·0001 0·94 0·003
Plasma TAG (mmol/l) 0·49b 0·07 0·54b 0·09 2·69a 0·43 0·65b 0·11 <0·0001 0·0002 <0·0001
Plasma total cholesterol (mmol/l) 1·54b 0·06 1·58b 0·09 1·99a 0·04 1·88a 0·08 <0·0001 0·62 0·29
Faecal lipid excretion (%) 7·37c 0·97 8·92c 0·45 14·37b 0·61 19·81a 1·52 <0·0001 0·002 0·06
C, corn starch; CIO, corn starch+ inulin oligofructose; H, high carbohydrate, high fat; HIO, high carbohydrate, high fat + inulin oligofructose.
a,b,c Mean values within a row with unlike superscript letters were significantly different (P<0·05).
* Body weight gain percentage calculated as percentage of body weight increased from 8 to 16 weeks for all groups.
Table 2. Fat mass development*
(Mean values with their standard errors; eight to ten rats per group)
C CIO H HIO P
Variables Mean SEM Mean SEM Mean SEM Mean SEM Diet Treatment Interaction
Total fat mass (g) 95·2b,c 4·9 69·6c 6·7 210·1a 14·9 121·5b 7·3 <0·0001 <0·0001 0·0021
Total lean mass (g) 279·0 2·7 299·9 7·9 279·1 10·9 308·5 7·4 0·581 0·0032 0·590
Abdominal circumference (cm) 18·2c 0·2 17·9c 0·2 21·9a 0·3 19·4b 0·2 <0·0001 <0·0001 <0·0001
Retroperitoneal fat (mg/mm) 122·6c 9·8 117·5c 20·8 359·5a 33·9 195·4b 16·4 <0·0001 0·0005 0·0009
Epididymal fat (mg/mm) 95·8c 6·0 93·4c 13·8 212·1a 15·4 139·2b 11·6 <0·0001 0·0040 0·0066
Omental fat (mg/mm) 56·8c 4·5 53·4c 6·2 116·5a 7·7 84·3b 6·9 <0·0001 0·0089 0·0315
Total abdominal fat (mg/mm) 275·1c 18·9 264·3c 40·1 688·0a 54·5 418·9b 32·3 <0·0001 0·0009 0·0020
Visceral adiposity index (%) 3·3c 0·2 3·2c 0·4 6·5a 0·5 4·7b 0·4 <0·0001 0·0201 0·0361
C, corn starch; CIO, corn starch+ inulin oligofructose; H, high carbohydrate, high fat; HIO, high carbohydrate, high fat + inulin oligofructose.
a,b,c Mean values within a row with unlike superscript letters were significantly different (P<0·05).
* Body weight gain percentage calculated as percentage of body weight increased from 8 to 16 weeks for all groups.
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and endothelium-independent relaxation to sodium nitroprusside
(Fig. 3(B)) compared with C and CIO rats (Table 5). IO decreased
SBP (Table 5) and increased vascular relaxant responses to both
acetylcholine and sodium nitroprusside, compared with H rats
(Fig. 3(C) and (B)). Using echocardiographic examination, most
of the cardiovascular parameters remained unchanged, but
increased SBP:LVIDs and ESS:LVIDs ratios demonstrated that
increased LV contractility was observed in H rats compared with
C rats (Table 5). IO treatment may improve LV contractility with
the normalised SBP:LVIDs and ESS:LVIDs ratios in HIO rats,
compared with the H rats (Table 5). The improvement in LV
contractility with IO treatment did not change either heart weight
or left ventricle + septum weight measurements in HIO rats
(Table 5). LV diastolic stiffness was increased in H rats and nor-
malised in HIO rats (Table 5). H rats showed increased inﬁltration
of inﬂammatory cells accompanied by enhanced collagen
deposition in the left ventricle compared with C and CIO rats
(Fig. 4(a), (b), (c), (e), (f) and (g)). Minimal inﬂammatory cell
inﬁltration and markedly reduced collagen deposition were
observed in HIO rats (Fig. 4(c), (d), (g) and (h)).
Table 3. Gastrointestinal weight and faecal output*
(Mean values with their standard errors; ten rats per group)
C CIO H HIO P
Variables Mean SEM Mean SEM Mean SEM Mean SEM Diet Treatment Interaction
Stomach (mg/mm) 80·4b 9·5 89·0b 8·6 133·2a 12·9 118·9a,b 13·7 0·052 0·566 0·132
Small intestine (cm) 143·5 2·2 139·7 4·4 148·8 1·8 142·2 1·7 0·165 0·067 0·614
Proximal colon (cm) 4·7 0·1 5·7 0·3 4·7 0·3 5·8 0·4 0·867 0·0011 0·867
Distal colon (cm) 3·7a 0·1 3·5a,b 0·3 3·0b 0·1 3·3a,b 0·1 0·0135 0·775 0·158
Total colon (cm) 8·3 0·2 9·2 0·5 7·8 0·3 9·1 0·4 0·420 0·005 0·590
Small intestine (mg/mm) 216·7b 9·8 209·9b 18·5 260·3a 5·3 231·2a,b 8·3 0·0081 0·130 0·342
Caecum (mg/mm) 80·9c 5·5 105·6b 4·0 101·1b 5·5 124·8a 5·0 0·0032 0·0003 0·497
Colon (mg/mm) 30·3c 1·9 53·3a 3·2 40·2b 3·5 56·9a 2·9 0·0275 <0·0001 0·2907
Total gut (mg/mm) 408·3b 21·7 457·8b 24·3 534·9a 18·2 525·6a 18·9 <0·0001 0·343 0·168
Faecal weight (g/12 h) 1·08d 0·14 2·95b 0·15 1·77c 0·11 3·42a 0·19 0·001 <0·0001 0·47
C, corn starch; CIO, corn starch+ inulin oligofructose; H, high carbohydrate, high fat; HIO, high carbohydrate, high fat + inulin oligofructose.
a,b,c,d Mean values within a row with unlike superscript letters were significantly different (P<0·05).
* Tissue wet weights were normalised with the tibial length (mg/mm).
(a) (b) (c) (d)
Fig. 1. Haematoxylin–eosin staining of the ileum (×20) showing inflammatory cells infiltration (a–d), with inflammatory cells marked as ‘in’, crypt cells (a–d) marked as
‘cry’, villi (a–d) marked as ‘vi’ and mucosal thickening (a–d) marked as ‘mt’ in rats fed corn starch diet (a), corn starch diet + inulin oligofructose (b), high-carbohydrate,
high-fat diet (c), high-carbohydrate, high-fat diet + inulin oligofructose (d).
Table 4. Hepatic structure and function and glycaemic profile
(Mean values with their standard errors; eight to ten rats per group)
C CIO H HIO P
Variables Mean SEM Mean SEM Mean SEM Mean SEM Diet Treatment Interaction
Liver weight (mg/mm) 243·5c 4·9 260·7b,c 11·2 342·6a 11·7 285·3b 10·3 <0·0001 0·050 0·0006
Plasma ALT activity (U/l) 29·6b 2·8 32·1b 2·9 43·9a 2·6 33·6b 2·0 0·005 0·14 0·019
Plasma AST activity (U/l) 74·4b 3·2 74·9b 4·2 96·8a 7·2 70·6b 3·2 0·07 0·011 0·009
Fasting blood glucose concentration (mmol/l) 4·5b 0·1 4·2b 0·1 5·2a 0·1 4·3b 0·1 0·0003 <0·0001 0·005
OGTT (AUC) (mmol/l per min)
Week 0 640·5 20·6 633·5 15·6 610·5 25·1 629·6 17·1 0·40 0·76 0·52
Week 8 654·8b 9·6 660·0b 14·5 826·1a 6·9 845·1a 11·4 <0·0001 0·277 0·533
Week 16 665·6c 14·7 653·4c 10·6 838·7a 20·3 728·7b 13·8 <0·0001 0·0004 0·0025
ITT (AUC) (mmol/l per min) 187·4c 24·4 155·2c 11·4 531·0a 18·5 323·9b 11·0 <0·0001 <0·0001 <0·0001
C, corn starch; CIO, corn starch+ inulin oligofructose; H, high carbohydrate, high fat; HIO, high carbohydrate, high fat + inulin oligofructose; ALT, alanine transaminase; AST,
aspartate transaminase; OGTT, oral glucose tolerance; ITT, insulin tolerance.
a,b,c Mean values within a row with unlike superscript letters were significantly different (P<0·05).
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Discussion
Intervention with IO in rats fed a high-carbohydrate, high-fat
diet improved gastrointestinal structure and function in this
study. We propose that these gastrointestinal changes led to
improvement in signs of the metabolic syndrome, allowing this
non-absorbed prebiotic to be deﬁned as a functional food for
this syndrome. We showed that IO did not affect food intake
but attenuated weight gain, potentially due to increased faecal
loss, as an increase in colonic motility(27) enhanced energy
excretion(28). Increased faecal lipid excretion in H rats treated
with IO is indirect evidence for incomplete intestinal fatty acid
absorption(27). The total energy expenditure mediated via
increased oxidation of endogenous fat may be increased to
(a) (b) (c) (d)
(e) (f) (g) (h)
Fig. 2. Haematoxylin–eosin staining of hepatocytes (×20) showing hepatocytes with enlarged fat vacuoles ((a–d), fat vacuoles marked as ‘fv’) and inflammatory cells
infiltration ((e–h), inflammatory cells marked as ‘in’) (20×) in rats fed corn starch diet (a, e), corn starch diet + inulin oligofructose (b, f), high-carbohydrate, high-fat diet
(c, g), high-carbohydrate, high-fat diet + inulin oligofructose (d, h).
Table 5. Cardiovascular structure and function
(Mean values with their standard errors)
C CIO H HIO P
Variables Mean SEM Mean SEM Mean SEM Mean SEM Diet Treatment Interaction
SBP (mmHg) 124b 2 118b 2 152a 2 123b 3 <0·0001 <0·0001 <0·0001
Heart rate (beats per min) 308·0a 24·1 237·0b 9·0 301·3a 17·2 259·9a,b 12·3 0·617 0·0014 0·363
LVIDd (mm) 7·73 0·22 7·71 0·12 7·87 0·18 7·95 0·18 0·295 0·868 0·781
LVIDs (mm) 4·40 0·22 4·10 0·22 4·17 0·21 4·42 0·24 0·841 0·911 0·227
IVSd (mm) 1·92 0·07 1·88 0·03 2·03 0·04 1·90 0·02 0·152 0·065 0·317
IVSs (mm) 3·07 0·13 3·17 0·10 3·19 0·16 2·89 0·10 0·527 0·430 0·121
LVPWd (mm) 1·79 0·11 1·88 0·03 1·99 0·04 1·83 0·03 0·238 0·578 0·054
LVPWs (mm) 2·79 0·07 2·99 0·28 2·96 0·11 2·95 0·11 0·695 0·567 0·527
Relative wall thickness 0·48 0·02 0·49 0·01 0·51 0·01 0·47 0·01 0·708 0·267 0·069
Systolic wall stress 97·2 5·8 85·2 9·4 107·2 8·0 91·6 5·5 0·274 0·071 0·808
Diastolic volume (µl) 493·0 39·2 481·0 22·4 517·0 34·7 532·0 35·9 0·275 0·965 0·691
Systolic volume (µl) 94·0 13·3 77·0 13·3 80·0 12·4 96·0 15·5 0·856 0·971 0·238
Stroke volume (µl) 399·0 31·3 404·0 17·7 437·0 29·3 436·0 30·1 0·216 0·943 0·914
Cardiac output (ml/min) 118·2 5·2 96·2 6·4 130·4 9·8 115·2 13·7 0·107 0·057 0·720
Fractional shortening (%) 45·0 3·0 49·3 1·1 47·2 2·1 46·5 1·7 0·887 0·397 0·242
Ejection fraction (%) 81·1 1·9 84·3 2·2 84·8 1·8 82·2 2·2 0·697 0·884 0·165
SBP:LVIDs 284b 16 291b 15 367a 19 281b 18 0·044 0·033 0·013
SBP:systolic volume 1538 252 1807 263 2192 293 1524 252 0·491 0·458 0·089
ESS:LVIDs 221b 8 206b 16 256a 10 208b 8 0·10 0·007 0·14
Diastolic stiffness (κ) 22·9b 0·6 22·9b 0·5 27·8a 0·5 22·6b 1·2 0·0045 0·0015 0·0015
Estimated LV mass (g) 1·09 0·09 1·09 0·04 1·25 0·06 1·14 0·03 0·089 0·364 0·364
LV+ septum wet weight (mg/mm)* 16·79b 0·36 16·21b 1·06 19·63a 0·57 17·82a,b 0·60 0·001 0·219 0·665
RV wet weight (mg/mm)* 2·24 0·10 2·54 0·18 2·76 0·16 2·39 0·23 0·343 0·689 0·030
C, corn starch; CIO, corn starch+ inulin oligofructose; H, high carbohydrate, high fat; HIO, high carbohydrate, high fat + inulin oligofructose; LVIDd, left ventricular internal diameter
thickness in diastole; LVIDs, left ventricular internal diameter thickness in systole; IVSd, interventricular septum thickness in diastole; IVSs, interventricular septum thickness in
systole; LVPWd, left ventricular posterior wall thickness in diastole; LVPWs, left ventricular posterior wall thickness in systole; ESS, end-systolic stress; LV, left ventricular; RV,
right ventricular.
a,b Mean values within a row with unlike superscript letters were significantly different (P<0·05).
* Tissue wet weights were normalised with the tibial length (mg/mm).
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compensate for this faecal energy loss accompanied by
increased faecal lipid excretion(29,30), thus reducing total body
fat as well as abdominal fat mass in HIO rats(31) (Table 2).
Our results differ from previous studies using rodents where
supplementation with 10–20% inulin and oligofructose in
comparison with 5% in this study prevented weight gain and
increased fat mass by reducing food intake via up-regulating the
expression of satiety hormones such as glucagon-like peptide-1
and peptide YY(32–34). Increased doses of inulin as a viscous
solution may produce stomach distension by increasing
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Fig. 3. Cumulative concentration–response curves for noradrenaline (A), sodium nitroprusside (B) and acetylcholine (C) in thoracic aortic rings from rats fed corn
starch (C, ), corn starch + inulin oligofructose (CIO, ), high-carbohydrate, high-fat diet (H, ), high-carbohydrate, high-fat + inulin oligofructose diet (HIO,
). Values are means, ten rats per group, with their standard errors represented by vertical bars. a,b Mean values with unlike letters are significantly different
(P< 0·05).
(a) (b) (c) (d)
(e) (f) (g) (h)
Fig. 4. Haematoxylin–eosin staining of the left ventricle (×20) showing infiltration of inflammatory cells ((a–d), inflammatory cells marked as ‘in’) in rats fed corn starch
diet (a), corn starch diet + inulin oligofructose (b), high-carbohydrate, high-fat diet (c), high-carbohydrate, high-fat diet + inulin oligofructose (d). Picrosirius
red staining of left ventricular interstitial collagen deposition ((e–h), fibrosis marked as ‘fi’) (20×) in rats fed corn starch diet (e), corn starch diet + inulin
oligofructose (f), high-carbohydrate, high-fat diet (g), high-carbohydrate, high-fat diet + inulin oligofructose (h).
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retention of water, thereby triggering the vagal responses
associated with satiety. The lower dose in our study may
improve gastrointestinal motility without stimulation of vagal
signals, thus not affecting appetite and food intake(35,36).
Inulin and oligofructose have been reported as effective
dietary ﬁbre producing minimal digestion in the stomach but
increased fermentation in the colon; these characteristics are
likely to provide physiological beneﬁts to metabolically
impaired patients, especially for the management of
obesity(36–38). Consumption of high-fat diets gradually slows
down gastric emptying because of the suppression of gastro-
intestinal motility(39,40). This is reﬂected in our study, as
high-carbohydrate, high-fat feeding increased stomach weight
by 66% and small intestine weight by 20% (Table 3). IO also
increased caecal weight with contents (19–23%) (Table 3); this
change has been directly linked to the increase in caecal pool
size accelerated by colonic fermentation of IO that produces
short-chain carboxylic acids such as acetate, butyrate and
propionate(41) and decreases caecal pH(37,42). Further, the
fermentation of IO improved intestinal colonic motility(16),
shown by increased colon weight with contents and higher
stool production(27,37) (Table 3) in IO rats. This improvement in
gastrointestinal motility with IO is likely to be associated with
increased growth of beneﬁcial gut microbes(43). Oral treatment
with inulin and oligofructose as a prebiotic mixture promoted
the growth of Biﬁdobacterium and Lactobacillus, with
softer stool production likely to improve the innate and
adaptive immune responses of younger children(44). Similarly,
high dietary ﬁbre treatment that comprised soluble prebiotics
including ﬁberosol-2, fructose-oligosaccharides and oligo-
isomaltose improved gut ecology with an increased popula-
tion count of Biﬁdobacterium pseudocatenulatum in
morbidly obese children of both genetic obesity and diet-
induced obesity phenotypes(45). This improvement in the gut
microbiota proﬁle reversed the dysmicrobiota-mediated toxic
metabolite production accompanied by reduced body weight
gain and improved metabolic proﬁle in these children(45).
The higher recruitment of lipopolysaccharide (LPS)-
containing gut microbes(46) expected in H diet-induced changes
in gut ﬂora decreased mucosal ileal wall thickness(46,47) with
more inﬂammation in the intestinal ileum(48,49), as shown in our
study. The growth of biﬁdobacteria should be enhanced by
IO(41) as well as by attenuation of obesity(50,51) and prevention
of LPS-induced inﬁltration of inﬂammatory cells in the intestinal
ileum(64), as in this study. Increased biﬁdobacteria could
attenuate the high-fat diet-induced translocation of LPS-
containing gut microbes(52,53) to improve gut-barrier
function with reduced intestinal ileal inﬂammation in HIO
rats. Further, increased secretion of gut hormones such as
glucagon-like peptide-2 with IO may lead to improved density
of ileal crypt cells and villi morphology(54,55) as in our study.
We also showed that IO improved insulin sensitivity and
glucose uptake, likely associated with diminished absorption of
ingested carbohydrates with decreased small intestinal transit
time(27,37). Further, the likely increase in propionate production
and absorption from the colon with IO may reduce plasma
concentrations of free fatty acids, and therefore inhibit hepatic
glucose production in HIO rats(56–58). In contrast to our study,
neither inulin nor oligofructose produced anti-hyperglycaemic
effects in rodents or humans, but the mechanisms of action to
improve glucose disposal and insulin sensitivity remain poorly
understood(37). The attenuation of total body fat mass accu-
mulation including visceral adiposity development by IO is the
likely reason for the improved lipid proﬁle(59) that prevented
the incidence of non-alcoholic fatty liver disease with reduced
inﬂammatory cell inﬁltration of hepatocytes in HIO rats(60–62).
IO supplementation in HIO rats improving ileal gut morphology
is likely to prevent the release and uptake of bacterial
endotoxins such as LPS through a leaky gut barrier and the
associated chronic systemic inﬂammation(63,64); this may pre-
cede the adipose tissue inﬂammation upon H diet feeding(65).
The reduction in endotoxaemia-mediated systemic inﬂamma-
tion(63,66) shown as reduced inﬁltration of inﬂammatory cells in
the intestinal ileum, heart and liver tissues may attenuate the
increased SBP with an improved vascular function in HIO
rats(67,68). Concomitantly, an anticipated reduction in leaky-
gut-mediated systemic inﬂammation, which may be regulated
by LPS-activated Toll-like receptor 4 signalling pathway in
either parenchyma or bone marrow cells(65,69), may contribute
to the reduced LV stiffness accompanied by reduced inﬁltration of
inﬂammatory cells(66) and collagen deposition in the left ventricle in
HIO rats(70,71). Further studies could conﬁrm the LPS-induced
systemic inﬂammation by measuring increased plasma or tissue
concentrations of pro-inﬂammatory cytokines such as monocyte
chemo-attractant protein 1, IL-6, interferon-γ or TNF-α(69). With this
improvement in cardiovascular structure, LV contractility was nor-
malised showing improved cardiovascular structure and function in
HIO rats. IO is an effective prebiotic that causes improvements in
ileal gut morphology and reduction in intestinal ileal inﬂammation
correlating with improvement in cardiovascular structure and
function in HIO rats.
The Dietitians Association of Australia recommend a daily
ﬁbre intake of 25–30 g(72). The human intake calculated from
the intake of IO in HIO rats would be 23·5–37·5 g/d based on
surface area comparisons(73), meeting these recommendations.
As a comparison, metabolic proﬁles were improved with a
marked decrease in body weight by altering the dysbiosis of gut
microbiota by administration of 49–51 g/d to children with
Prader–Willi syndrome or simple obesity(45).
In conclusion, our results indicate that IO treatment
contributed to the attenuation of H diet-induced metabolic
complications in HIO rats by improving gut structure and
function. IO treatment was associated with reduction in
visceral adiposity development; improvement in impaired oral
glucose and insulin tolerance, lipid proﬁle, liver structure and
function; reduction in inﬁltration of inﬂammatory cells into
the heart and liver; reduction in SBP with an improved vascular
function; and improved cardiovascular structure and function
with an improved LV contractility. This model mimics the
changes in diet-induced obesity in humans(14) and we have
used a dose recommended for humans(67). Thus, our results
suggest that this dose of about 30 g IO/d would be sufﬁcient to
ameliorate diet-induced metabolic complications in adult
humans. Further studies could include analysis of the gut
microbiome to determine bacteria that are most affected by
chronic IO treatment.
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